Journal article

Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells

Ashleigh R Poh, Robert JJ O'Donoghue, Matthias Ernst



The hematopoietic cell kinase (HCK) is a member of the SRC family of cytoplasmic tyrosine kinases (SFKs), and is expressed in cells of the myeloid and B-lymphocyte cell lineages. Excessive HCK activation is associated with several types of leukemia and enhances cell proliferation and survival by physical association with oncogenic fusion proteins, and with functional interactions with receptor tyrosine kinases. Elevated HCK activity is also observed in many solid malignancies, including breast and colon cancer, and correlates with decreased patient survival rates. HCK enhances the secretion of growth factors and pro-inflammatory cytokines from myeloid cells, and promotes macrophage polarizat..

View full abstract


Awarded by Victorian Cancer Agency

Awarded by NHMRC

Funding Acknowledgements

The work in the laboratory of M.E is supported by Ludwig Cancer Research, the Victorian State Government Operational Infrastructure Support, the IRIISS scheme of the National Health and Medical Research Council Australia (NHMRC), and NHMRC grants #1069024, #1067244 and #1081373 awarded to M.E. A.R.P is supported by an Australian Postgraduate Award. R.O'D received project grant support from NHMRC (#1025239) and the Victorian Cancer Agency (ECSG13014). M.E is a NHMRC Principal Research Fellow.